{"filings":[{"id":1112797,"accession_number":"0002077096-26-000203","cik":816956,"company_name":"CONMED Corp","ticker":"CNMD","form_type":"8-K","filed_at":"2026-06-17T20:49:40+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"CONMED appoints John E. Gallagher as CFO effective July 15, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Gallagher joins from Certara (CFO); previously CFO at Cue Health and SVP/CFO at BD Medical Segment.","Base salary $650,000; target bonus 85%; equity grants valued at $2.3M plus $1.5M make-up RSUs.","Outgoing CFO Todd Garner stays in advisory capacity through November 2, 2026.","President/CEO Patrick Beyer and Kimberly Lockwood cease interim CFO/accounting roles on effective date.","Gallagher eligible for severance under CONMED Executive Severance Plan (1.5x base + average bonus)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1068274236.9273432,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":843157,"accession_number":"0001174947-26-000639","cik":816956,"company_name":"CONMED Corp","ticker":"CNMD","form_type":"8-K","filed_at":"2026-06-04T11:30:38+00:00","items":["1.01","9.01"],"status":"ready","headline":"CONMED repurchases $645M of 2.25% convertible notes due 2027 for $637M cash","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Principle amount of $645.2M at 2.25% coupon due 2027 acquired for $637.2M in cash.","Closing expected June 15, 2026, subject to customary conditions.","Deal reduces outstanding convertible debt and potential future dilution.","Repurchases conducted through privately negotiated agreements with certain holders.","Company retains J. Wood Capital Advisors as advisor for the transaction."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1068274236.9273432,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":759957,"accession_number":"0002077096-26-000190","cik":816956,"company_name":"CONMED Corp","ticker":"CNMD","form_type":"8-K","filed_at":"2026-06-01T12:31:19+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"CONMED secures $450M incremental term loan facility to repurchase convertible notes due 2026","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Aggregate $450M in incremental delayed draw term A-2 loans available for single draw on or before June 14, 2026.","Proceeds to repurchase a portion of CONMED's outstanding 2.25% Convertible Senior Notes due 2026 and pay fees.","Term A-2 Facility matures June 10, 2030; interest rate SOFR + 1.125%-2.25% (initial 1.75% for SOFR).","Amends existing Credit Agreement and Guarantee and Collateral Agreement; lenders include JPMorgan, PNC, Goldman Sachs, BofA, Wells Fargo, DNB, Capital One, Hancock Whitney.","Facility is secured by same assets and guaranteed by same subsidiaries as existing credit obligations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1068274236.9273432,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":536757,"accession_number":"0000816956-26-000057","cik":816956,"company_name":"CONMED Corp","ticker":"CNMD","form_type":"8-K","filed_at":"2026-05-20T12:30:27+00:00","items":["5.02","5.03","5.07","9.01"],"status":"ready","headline":"CONMED appoints two new directors from J&J and Boston Scientific; Board expands to nine","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Appointed Celine Martin (ex-J&J MedTech exec) and Jeff Mirviss (ex-Boston Scientific exec) to Board, effective July 1, 2026.","Martin to serve on Audit and Strategy Committees; Mirviss on Compensation and Governance Committees.","Appointed Kimberly Lockwood as Interim Corporate Controller and Principal Accounting Officer, effective June 1, 2026.","Stockholders elected seven directors, approved say-on-pay, and ratified PwC as auditor for fiscal 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1068274236.9273432,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":99034,"accession_number":"0000816956-26-000051","cik":816956,"company_name":"CONMED Corp","ticker":"CNMD","form_type":"8-K","filed_at":"2026-04-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CONMED Q1 2026: GAAP EPS $0.45, adjusted EPS $0.89; raises FY organic revenue growth guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Sales $317.0M (-1.3% YoY); domestic -5.8%, international +4.7% as reported.","GAAP EPS $0.45 vs $0.19 YoY; adjusted EPS $0.89 vs $0.95.","FY 2026 organic constant currency revenue growth guidance raised to 5.0-6.5% from 4.5-6.0%.","Reported revenue guidance raised to $1.350-1.375B; adjusted EPS reaffirmed $4.30-$4.45.","GI product exit impacted sales by $15.5M; company focusing on higher-growth areas."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1068274236.9273432,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":114827,"accession_number":"0001213900-26-027658","cik":816956,"company_name":"CONMED Corp","ticker":"CNMD","form_type":"8-K","filed_at":"2026-03-13T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"CONMED names VP & Corporate Controller Andrew Moller as Interim Principal Financial Officer","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Andrew Moller, 51, appointed Interim Principal Financial Officer effective March 15, 2026.","Moller joined CONMED Jan 2025 as VP, Corp Controller; became Principal Accounting Officer Apr 2025.","Previously Global Controller & CFO Asia-Pacific at Smith & Nephew; prior roles at Stanley Black & Decker.","No change in compensation or related-party transactions for Moller's appointment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1068274236.9273432,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":114826,"accession_number":"0000816956-26-000006","cik":816956,"company_name":"CONMED Corp","ticker":"CNMD","form_type":"8-K","filed_at":"2026-01-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CONMED Q4 sales up 7.9%, adjusted EPS $1.43; FY2026 guidance below 2025 adjusted EPS","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 sales $373.2M (+7.9% YoY); GAAP EPS $0.54 vs $1.08, adjusted EPS $1.43 vs $1.34.","FY2025 sales $1.3747B (+5.2%); GAAP EPS $1.51 vs $4.25, adjusted EPS $4.59 vs $4.17.","FY2026 guidance: revenue $1.345B-$1.375B (organic constant-currency growth 4.5%-6% ex-gastro), adj. EPS $4.30-$4.45.","International Q4 revenue +17% (reported) vs domestic +1.4%; Orthopedic Surgery segment +13.2%.","GAAP results weighed by ~$60M in Q4 operating charges including optimization and product rationalization."],"consensus_eps_estimate":null,"consensus_eps_actual":1.51,"consensus_revenue_estimate":null,"consensus_revenue_actual":1374724000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1068274236.9273432,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":114825,"accession_number":"0001174947-26-000024","cik":816956,"company_name":"CONMED Corp","ticker":"CNMD","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"CONMED provides preliminary 2026 guidance at J.P. Morgan Healthcare Conference; no figures in filing","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Presented at J.P. Morgan 44th Annual Healthcare Conference on January 12, 2026.","Preliminary 2026 financial guidance was included in the investor presentation.","No specific revenue, EPS, or other guidance figures were disclosed in the filing text.","Presentation available on CONMED's website under Investors > Presentations.","CFO Todd W. Garner and CEO Pat J. Beyer presented."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1068274236.9273432,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":114824,"accession_number":"0001174947-26-000017","cik":816956,"company_name":"CONMED Corp","ticker":"CNMD","form_type":"8-K","filed_at":"2026-01-08T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"CONMED CFO Todd Garner to depart; transition to Special Advisor through Nov 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Garner's separation effective by Mar 15, 2026 or upon appointment of new CFO; he will serve as Special Advisor until Nov 2, 2026.","Garner eligible for severance under Executive Severance Plan: 1.5x salary + 1.5x average bonus; equity continues vesting through Separation Date.","Company retained executive search firm for permanent CFO; separation not due to disagreement on operations, policies, financial results.","Garner will receive base salary and pro-rated bonus during advisory period but will not receive annual equity grant in Q1 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1068274236.9273432,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131208,"accession_number":"0001213900-25-118476","cik":816956,"company_name":"CONMED Corp","ticker":"CNMD","form_type":"8-K","filed_at":"2025-12-05T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"CONMED to exit gastroenterology lines; terminates Gore VIABIL agreement effective Jan 1, 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gastroenterology product lines expected to generate $90M–$95M revenue in 2025 with ~45% gross margins.","Exit projected to cause EPS dilution of $0.45–$0.55 in 2026.","Consolidated gross margin expected to improve by ~80 bps after exit completion.","CONMED reaffirms full-year 2025 revenue guidance of $1.365B–$1.372B and adjusted EPS of $4.48–$4.53.","2026 guidance to be provided on Q4 2025 earnings call."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1068274236.9273432,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131207,"accession_number":"0000816956-25-000054","cik":816956,"company_name":"CONMED Corp","ticker":"CNMD","form_type":"8-K","filed_at":"2025-11-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CONMED Q3 revenue up 6.7% to $338M; adjusted EPS $1.08; suspends dividend, authorizes $150M buyback","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Diluted GAAP EPS $0.09 vs $1.57 YoY due to $19.7M product rationalization and $9.2M consulting costs.","Adjusted diluted EPS $1.08 vs $1.05 YoY; full-year adjusted EPS guidance raised to $4.48-$4.53.","Full-year revenue guidance narrowed to $1.365B-$1.372B; tariffs expected to reduce Q4 EPS by ~$0.07.","Board authorized $150M share repurchase program; quarterly cash dividend suspended; at least $25M annual buybacks from 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":0.97,"consensus_revenue_estimate":null,"consensus_revenue_actual":1001526000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1068274236.9273432,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":147798,"accession_number":"0001174947-25-001185","cik":816956,"company_name":"CONMED Corp","ticker":"CNMD","form_type":"8-K","filed_at":"2025-09-09T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"CONMED appoints Kim Kelderman to Board of Directors effective Sept 8, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Kim Kelderman appointed to CONMED's Board, effective September 8, 2025.","He serves on Corporate Governance & Nominating and Strategy Committees.","Kelderman is President & CEO of Bio-Techne (TECH) since February 2024.","Granted prorated equity valued at ~$134,766 (500 RSUs + options for 6,227 shares).","Prior roles include Thermo Fisher Scientific and Becton Dickinson."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":1068274236.9273432,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":147797,"accession_number":"0000816956-25-000031","cik":816956,"company_name":"CONMED Corp","ticker":"CNMD","form_type":"8-K","filed_at":"2025-08-08T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"CONMED declares $0.20 quarterly dividend, payable Oct 3, 2025","summary_kind":"llm","event_type":"dividend","confidence":"high","bullets":["Quarterly cash dividend of $0.20 per share declared on August 7, 2025.","Payable on October 3, 2025, to shareholders of record as of September 15, 2025.","No change in dividend amount from prior quarter."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":1068274236.9273432,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":147796,"accession_number":"0000816956-25-000026","cik":816956,"company_name":"CONMED Corp","ticker":"CNMD","form_type":"8-K","filed_at":"2025-07-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CONMED Q2 adj EPS $1.15 beats; raises FY2025 revenue and adj EPS guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 sales $342.3M (+3.1% YoY); GAAP EPS $0.69 (down from $0.96), adj EPS $1.15 (up from $0.98).","Single-use products +6.6% to $297.8M; capital products -15.5% to $44.5M.","FY revenue guidance raised to $1.356B-1.378B; adj EPS raised to $4.40-4.55 (prior $4.31-4.46).","Company estimates ~$0.09 EPS headwind from tariffs in H2 2025.","Operational optimization consulting fees $7.6M in Q2; exec transition costs $12.2M YTD."],"consensus_eps_estimate":null,"consensus_eps_actual":0.88,"consensus_revenue_estimate":null,"consensus_revenue_actual":663600000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1068274236.9273432,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":147795,"accession_number":"0001174947-25-000987","cik":816956,"company_name":"CONMED Corp","ticker":"CNMD","form_type":"8-K","filed_at":"2025-07-07T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"CONMED director Martha Aronson resigns to become Merit Medical President & CEO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Martha Aronson resigned from CONMED board effective July 7, 2025 to become President and CEO of Merit Medical Systems.","No disagreement between Aronson and CONMED; resignation for external opportunity.","Aronson served on CONMED board since 2016 and previously served as Chair.","Chair LaVerne Council thanked Aronson for her strategic contributions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1068274236.9273432,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":166493,"accession_number":"0001174947-25-000941","cik":816956,"company_name":"CONMED Corp","ticker":"CNMD","form_type":"8-K","filed_at":"2025-06-16T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"CONMED enters into $750M credit agreement; maturities extended to 2030","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["New $550M USD revolver, $100M multicurrency revolver, and $100M term loan; maturity date June 10, 2030.","Proceeds used to repay existing term loan ($100M) and $16M of revolving amounts under prior credit agreement.","Removed fixed charge coverage ratio; added minimum interest coverage ratio of 2.75:1 (tested quarterly).","Removed mandatory prepayments on excess cash flow and updated interest rate margins (e.g., Term Benchmark Loans at 1.125% p.a.).","Credit agreement includes senior secured leverage ratio ≤3.75:1 and total leverage ratio ≤5.50:1 with step-ups for acquisitions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1068274236.9273432,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":166492,"accession_number":"0001174947-25-000828","cik":816956,"company_name":"CONMED Corp","ticker":"CNMD","form_type":"8-K","filed_at":"2025-05-21T23:59:59+00:00","items":["5.02","5.07","8.01","9.01"],"status":"ready","headline":"CONMED declares $0.20 dividend; shareholders approve 2025 LTIP and reelect directors","summary_kind":"llm","event_type":"dividend","confidence":"high","bullets":["Quarterly cash dividend of $0.20/share declared, payable July 3, 2025 to holders of record June 13, 2025.","Eight directors reelected at May 20 annual meeting; each received >28M votes for election.","Advisory say-on-pay passed with 27.9M for, 0.9M against, 25.6K abstentions.","2025 Long-Term Incentive Plan approved with 22.0M for, 6.8M against, 25.1K abstentions.","Ratification of PwC as fiscal 2025 auditor approved with 27.7M for, 2.0M against, 6.4K abstentions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1068274236.9273432,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":166491,"accession_number":"0001174947-25-000654","cik":816956,"company_name":"CONMED Corp","ticker":"CNMD","form_type":"8-K","filed_at":"2025-04-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CONMED Q1 adjusted EPS $0.95, revenue $321.3M, raises FY2025 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total sales $321.3M, up 2.9% reported (3.8% constant currency); domestic +4.2%, international +1.2%.","GAAP diluted EPS $0.19 vs $0.63 YoY, hit by $12.2M executive transition costs and $4.0M contingent consideration.","Adjusted diluted EPS $0.95, up 20% from $0.79; adjusted EBITDA $61.3M (19.1% margin) vs $56.3M.","FY2025 revenue guidance raised to $1.350-1.378B (prior $1.344-1.372B); adjusted EPS raised to $4.45-4.60 (prior $4.25-4.40).","Company estimates ~$0.14 negative tariff impact on EPS in H2 2025, not included in updated guidance."],"consensus_eps_estimate":null,"consensus_eps_actual":0.19,"consensus_revenue_estimate":null,"consensus_revenue_actual":321256000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1068274236.9273432,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":166490,"accession_number":"0001174947-25-000453","cik":816956,"company_name":"CONMED Corp","ticker":"CNMD","form_type":"8-K","filed_at":"2025-04-01T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"CONMED appoints Andrew Moller as Principal Accounting Officer effective April 1, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Andrew Moller, 50, appointed Principal Accounting Officer; joined as VP Corporate Controller on Jan 27, 2025.","Todd W. Garner ceases as Principal Accounting Officer but remains EVP Finance & CFO.","Kimberly A. Lockwood promoted to Senior Director of Financial Reporting from Interim Corporate Controller.","Moller previously served as VP Global Process Owner – Finance at Smith & Nephew plc (2019-2025)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1068274236.9273432,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":183922,"accession_number":"0001174947-25-000234","cik":816956,"company_name":"CONMED Corp","ticker":"CNMD","form_type":"8-K","filed_at":"2025-02-25T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"CONMED appoints Mark Kaye as director; declares $0.20 quarterly dividend","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board expanded to nine; Mark Kaye appointed effective Feb 24, 2025, with Audit and Strategy committee assignments.","Quarterly dividend of $0.20 per share declared, payable April 4, 2025 to holders of record March 14, 2025.","Kaye currently EVP & CFO of Elevance Health; previously CFO of Moody's and senior finance roles at MassMutual and ING.","Kaye received prorated equity grant of 152 RSUs and options on 1,846 shares, vesting in full on Feb 24, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1068274236.9273432,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":183921,"accession_number":"0001174947-25-000129","cik":816956,"company_name":"CONMED Corp","ticker":"CNMD","form_type":"8-K","filed_at":"2025-02-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CONMED Q4 2024 sales $345.9M (+5.8% YoY), adjusted EPS $1.34; FY25 guidance issued","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 GAAP diluted EPS $1.08 (vs $1.05 YoY); adjusted diluted EPS $1.34 (+26.4%).","Full-year 2024 sales $1,307.0M (+5.0% reported); adjusted EPS $4.17 vs $3.45 in 2023.","Q4 single-use product sales +9.6% YoY; capital product sales declined 12.7%.","FY2025 guidance: revenue $1.344-1.372B (4-6% constant currency growth); adjusted EPS $4.25-4.40."],"consensus_eps_estimate":null,"consensus_eps_actual":4.25,"consensus_revenue_estimate":null,"consensus_revenue_actual":1307015000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1068274236.9273432,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":183920,"accession_number":"0001193125-25-005046","cik":816956,"company_name":"CONMED Corp","ticker":"CNMD","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"CONMED presents at J.P. Morgan Healthcare Conference; presentation content not extractable from filing excerpt","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Investor presentation for the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025.","Presentation is available on CONMED's website under Investors section.","No specific financial updates, guidance changes, or material data are provided in the truncated exhibit."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":1068274236.9273432,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":200514,"accession_number":"0001174947-24-001328","cik":816956,"company_name":"CONMED Corp","ticker":"CNMD","form_type":"8-K","filed_at":"2024-12-10T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"CONMED declares $0.20 quarterly dividend payable Jan 3, 2025","summary_kind":"llm","event_type":"dividend","confidence":"high","bullets":["Quarterly cash dividend of $0.20 per share declared on December 9, 2024.","Dividend payable on January 3, 2025 to shareholders of record as of December 20, 2024.","Dividend amount unchanged from prior quarter; no indication of change in policy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1068274236.9273432,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":200513,"accession_number":"0001193125-24-247545","cik":816956,"company_name":"CONMED Corp","ticker":"CNMD","form_type":"8-K","filed_at":"2024-10-30T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"CONMED Q3 2024: adj. EPS $1.05 beats; revenue guidance trimmed; CEO transition to Beyer Jan 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Sales $316.7M (+4.0% YoY); GAAP EPS $1.57 (vs $0.50); adjusted EPS $1.05 (+16.7%).","Full-year revenue guidance lowered to $1.300–1.305B from $1.305–1.315B; adj. EPS raised to $4.00–4.05 from $3.95–4.02.","COO Pat Beyer appointed President and CEO effective Jan 1, 2025; Curt Hartman will retire and serve as Special Advisor through March 2027.","Hartman to receive consulting fee of $1.936M plus 2x avg bonus; equity vesting continues through separation date.","Domestic sales +7.4% YoY; international -0.4%; single-use products +6.9%, capital -10.6%."],"consensus_eps_estimate":null,"consensus_eps_actual":3.17,"consensus_revenue_estimate":null,"consensus_revenue_actual":961071000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1068274236.9273432,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":200512,"accession_number":"0001193125-24-232621","cik":816956,"company_name":"CONMED Corp","ticker":"CNMD","form_type":"8-K","filed_at":"2024-10-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CONMED prelim Q3 rev $315-318M; adj EPS growth to exceed 9-11% guide","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue expected $315M-$318M for Q3 2024 (preliminary).","Adjusted diluted EPS growth exceeds previously guided 9%-11% range.","Full Q3 results to be reported Oct 30, 2024 after market close.","Data is preliminary; may change upon completion of financial close."],"consensus_eps_estimate":null,"consensus_eps_actual":3.17,"consensus_revenue_estimate":null,"consensus_revenue_actual":961071000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1068274236.9273432,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":216538,"accession_number":"0001193125-24-228650","cik":816956,"company_name":"CONMED Corp","ticker":"CNMD","form_type":"8-K","filed_at":"2024-09-30T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"CONMED: Hurricane Helene caused ~24-hour shutdown at Largo plant; employees safe, facilities back to normal","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Manufacturing facility in Largo, FL and distribution center in Lithia Springs, GA were impacted.","Manufacturing ceased for approximately 24 hours; significant employee absences temporarily affected production.","No significant damage at either facility; both are back to normal operations as of Sept 30.","Company reports customers in SE US delayed surgeries; financial impact not yet estimable.","All employees confirmed safe."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1068274236.9273432,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":216537,"accession_number":"0001193125-24-222986","cik":816956,"company_name":"CONMED Corp","ticker":"CNMD","form_type":"8-K","filed_at":"2024-09-20T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"CONMED Corp corporate controller leaving Sept 27; interim and accounting officer changes","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Eric B. Staves, VP Corporate Controller, departs Sept 27 for an executive opportunity elsewhere.","Kimberly A. Lockwood, Director of Financial Reporting & Controls, named Interim Corporate Controller effective Sept 30.","Todd W. Garner, EVP/CFO, assumes role of Principal Accounting Officer.","Retired VP Terence M. Berge continues as Special Advisor to support transition."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":1068274236.9273432,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":216536,"accession_number":"0001193125-24-200674","cik":816956,"company_name":"CONMED Corp","ticker":"CNMD","form_type":"8-K","filed_at":"2024-08-14T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"CONMED President Bill Peters to depart on August 31, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Employment of Stanley W. (Bill) Peters, President of Advanced Surgical & Advanced Endoscopic Technologies, terminates Aug 31, 2024.","Mr. Peters will receive compensation per the non-change in control qualifying termination under the Executive Severance Plan.","No successor named in the filing.","Departure is effective August 31, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1068274236.9273432,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":216535,"accession_number":"0001174947-24-000987","cik":816956,"company_name":"CONMED Corp","ticker":"CNMD","form_type":"8-K","filed_at":"2024-08-09T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"CONMED declares $0.20 quarterly dividend, payable Oct 4, 2024","summary_kind":"llm","event_type":"dividend","confidence":"high","bullets":["Quarterly cash dividend of $0.20 per share declared on August 9, 2024.","Dividend payable October 4, 2024 to shareholders of record as of September 16, 2024.","This is a regular dividend declaration; no change in dividend rate from prior quarter."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1068274236.9273432,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":216534,"accession_number":"0001174947-24-000936","cik":816956,"company_name":"CONMED Corp","ticker":"CNMD","form_type":"8-K","filed_at":"2024-07-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CONMED Q2 adj EPS $0.98 beats; cuts FY revenue & EPS guidance on supply chain delays","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $332.1M (+4.5% reported, +5.2% constant currency); GAAP EPS $0.96 vs $0.43; adj EPS $0.98 vs $0.83 (+18.1%).","Full-year revenue guidance lowered to $1.305-1.315B from $1.330-1.355B; adj EPS guidance cut to $3.95-4.02 from $4.25-4.35.","CEO cites unresolved supply chain challenges delaying commercial reacceleration, impacting second half outlook.","Orthopedic Surgery sales -0.9% YoY; General Surgery +8.9%; Domestic +6.1%, International +2.6% reported.","Adjusted EBITDA $64.6M (19.4% margin) vs $57.6M (18.1%) in Q2 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":1.59,"consensus_revenue_estimate":null,"consensus_revenue_actual":644371000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1068274236.9273432,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":236180,"accession_number":"0001174947-24-000761","cik":816956,"company_name":"CONMED Corp","ticker":"CNMD","form_type":"8-K","filed_at":"2024-05-28T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"CONMED announces retirement of VP Corporate Controller Berge, promotion of Staves","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Terence M. Berge to retire as VP, Corporate Controller effective June 30, 2024, then serve as Special Advisor.","Eric B. Staves promoted to VP, Corporate Controller effective July 1, 2024.","Staves previously served as VP of Corporate Finance since March 2023; earlier VP of Finance for CONMED Orthopedics.","Staves to receive 3,000 restricted stock units under the company's long-term incentive plan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1068274236.9273432,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":236179,"accession_number":"0001104659-24-064334","cik":816956,"company_name":"CONMED Corp","ticker":"CNMD","form_type":"8-K","filed_at":"2024-05-22T23:59:59+00:00","items":["5.07","8.01"],"status":"ready","headline":"CONMED declares $0.20 quarterly dividend payable July 5, 2024","summary_kind":"llm","event_type":"dividend","confidence":"high","bullets":["Quarterly cash dividend of $0.20 per share declared on May 22, 2024.","Payable July 5, 2024 to holders of record as of June 14, 2024.","All eight director nominees elected; say-on-pay and auditor ratification passed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":1068274236.9273432,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":236178,"accession_number":"0001193125-24-110117","cik":816956,"company_name":"CONMED Corp","ticker":"CNMD","form_type":"8-K","filed_at":"2024-04-24T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"CONMED promotes Pat Beyer to COO; Heather Cohen transitions to Special Advisor","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Pat Beyer promoted to COO effective Apr 24, 2024; salary £478,225, 80% STIP target, $800k one-time equity grant (75% options, 25% PSUs).","Heather Cohen moves from EVP & Chief HR & Legal Officer to Special Advisor Apr 20, 2024–Apr 19, 2025; paid $668,226.50 salary plus potential $334,113.25 in 2026.","Cohen's equity awards continue vesting through Apr 19, 2025; vestings after that date forfeited. Subject to cooperation and non-compete covenants.","Cohen agrees to cooperate with Company and DOJ review on royalty payments; restricted from competing/soliciting for one year post-service."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1068274236.9273432,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":236177,"accession_number":"0001174947-24-000582","cik":816956,"company_name":"CONMED Corp","ticker":"CNMD","form_type":"8-K","filed_at":"2024-04-24T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CONMED Q1 2024: revenue up 5.7% to $312.3M; adjusted EPS $0.79 beats; guidance trimmed on FX headwinds","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP diluted EPS $0.63 vs $0.06 in Q1 2023; adjusted EPS $0.79, up 19.7% YoY.","Revenue $312.3M (+5.7% as reported, +5.9% constant currency); domestic +7.2%, international +3.8%.","General Surgery revenue grew 8.0% as reported; Orthopedic Surgery +2.8%.","FY2024 revenue guidance lowered to $1.330-1.355B (prev $1.340-1.365B) due to ~$10M FX headwind.","Adjusted EBITDA $56.3M, margin 18.0% vs 17.3% in Q1 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":0.63,"consensus_revenue_estimate":null,"consensus_revenue_actual":312273000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1068274236.9273432,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":253882,"accession_number":"0001174947-24-000261","cik":816956,"company_name":"CONMED Corp","ticker":"CNMD","form_type":"8-K","filed_at":"2024-02-27T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"CONMED declares quarterly dividend of $0.20 per share","summary_kind":"llm","event_type":"dividend","confidence":"high","bullets":["Board declared quarterly cash dividend of $0.20 per share.","Dividend payable on April 5, 2024.","Record date: shareholders as of March 15, 2024.","No change from prior quarterly dividend rate."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":1068274236.9273432,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":253881,"accession_number":"0001174947-24-000144","cik":816956,"company_name":"CONMED Corp","ticker":"CNMD","form_type":"8-K","filed_at":"2024-01-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CONMED Q4 sales $327M (+30.4% YoY); adjusted EPS $1.06 (+152%); guides FY24 rev $1.34-1.365B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 sales $327.0M, +30.4% YoY (31.5% constant currency); domestic +33.3%, intl +26.5% as reported.","Q4 GAAP diluted EPS $1.05; adjusted diluted EPS $1.06, up 152.4% vs Q4 2022.","FY2023 sales $1,244.7M (+19.1%); GAAP EPS $2.04 vs loss of $2.68; adjusted EPS $3.45 (+30.2%).","FY2024 revenue guidance $1.340B-$1.365B (8-10% growth); adjusted EPS guidance $4.30-$4.40 (25-28% growth).","Record revenue achieved in both Q4 and full year; balanced growth across General Surgery and Orthopedics."],"consensus_eps_estimate":null,"consensus_eps_actual":2.04,"consensus_revenue_estimate":null,"consensus_revenue_actual":1244744000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1068274236.9273432,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":271329,"accession_number":"0001174947-23-001426","cik":816956,"company_name":"CONMED Corp","ticker":"CNMD","form_type":"8-K","filed_at":"2023-12-05T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"CONMED declares $0.20 quarterly dividend payable Jan 5, 2024","summary_kind":"llm","event_type":"dividend","confidence":"high","bullets":["Quarterly cash dividend of $0.20 per share declared on December 4, 2023.","Payable on January 5, 2024 to shareholders of record as of December 18, 2023.","Dividend amount unchanged from prior quarter; no special dividend announced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1068274236.9273432,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":271328,"accession_number":"0001174947-23-001234","cik":816956,"company_name":"CONMED Corp","ticker":"CNMD","form_type":"8-K","filed_at":"2023-10-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CONMED Q3 sales $304.6M (+10.7% YoY); adj. EPS $0.90 (+16.9%); raises FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue of $304.6M, +10.7% reported (+11.9% constant currency). Domestic +9.5%, International +12.3%.","GAAP diluted EPS $0.50 (vs $1.48); Adjusted diluted EPS $0.90, up 16.9% from $0.77.","General Surgery sales $179.9M (+15% reported); Orthopedic Surgery $124.7M (+5.1%).","Full-year revenue guidance raised to $1.24B-$1.26B; adj. EPS guidance raised to $3.45-$3.55.","Adjusted EBITDA margin 19.6% vs 19.4% prior year."],"consensus_eps_estimate":null,"consensus_eps_actual":0.99,"consensus_revenue_estimate":null,"consensus_revenue_actual":917699000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1068274236.9273432,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":288192,"accession_number":"0001174947-23-001001","cik":816956,"company_name":"CONMED Corp","ticker":"CNMD","form_type":"8-K","filed_at":"2023-08-10T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"CONMED declares $0.20 quarterly dividend payable Oct 5, 2023","summary_kind":"llm","event_type":"dividend","confidence":"high","bullets":["Quarterly cash dividend of $0.20 per share announced on August 10, 2023.","Payable on October 5, 2023 to shareholders of record as of September 15, 2023.","Dividend is a cash distribution to common shareholders (CNMD)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1068274236.9273432,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":288191,"accession_number":"0001174947-23-000915","cik":816956,"company_name":"CONMED Corp","ticker":"CNMD","form_type":"8-K","filed_at":"2023-07-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CONMED Q2 sales +14.6% to $317.7M, adj. EPS $0.83, raises FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP diluted EPS $0.43 vs loss of $5.65; adjusted diluted EPS $0.83, +9.2% YoY.","Revenue $317.7M (+14.6% as reported, +16.6% constant currency); acquisitions added ~400 bps.","Domestic sales +17.1%; International sales +11.7% as reported (+16.0% constant currency).","Orthopedic Surgery +17.1%, General Surgery +12.6% as reported.","FY 2023 revenue guidance raised to $1.230-1.260B; adjusted EPS guidance raised to $3.40-3.55."],"consensus_eps_estimate":null,"consensus_eps_actual":0.49,"consensus_revenue_estimate":null,"consensus_revenue_actual":613121000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1068274236.9273432,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":308639,"accession_number":"0001193125-23-152961","cik":816956,"company_name":"CONMED Corp","ticker":"CNMD","form_type":"8-K","filed_at":"2023-05-24T23:59:59+00:00","items":["5.07","8.01"],"status":"ready","headline":"CONMED declares $0.20 quarterly dividend payable July 5, 2023","summary_kind":"llm","event_type":"dividend","confidence":"high","bullets":["Quarterly cash dividend of $0.20 per share declared; payable July 5, 2023 to holders of record June 15, 2023.","All nine director nominees elected at annual meeting; each received >26.8M votes for.","Advisory say-on-pay approved with 26.5M for, 1.8M against; amendment to certificate for officer exculpation passed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1068274236.9273432,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":308638,"accession_number":"0001174947-23-000616","cik":816956,"company_name":"CONMED Corp","ticker":"CNMD","form_type":"8-K","filed_at":"2023-04-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CONMED Q1 sales $295.5M (+21.9% YoY); raises FY 2023 revenue and EPS guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Sales $295.5M (+21.9% as reported; +25.1% constant currency); acquisitions contributed ~570 bps growth.","GAAP diluted EPS $0.06 (down 87.2% YoY); adjusted diluted EPS $0.66 (down 5.7% YoY).","Raises FY 2023 revenue guidance to $1.205B-$1.250B from $1.170B-$1.220B.","Raises FY 2023 adjusted EPS guidance to $3.30-$3.50 from $3.20-$3.45.","Adjusted EBITDA $51.2M (17.3% margin) vs $43.7M (18.0% margin) in Q1 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":0.06,"consensus_revenue_estimate":null,"consensus_revenue_actual":295468000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1068274236.9273432,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":327420,"accession_number":"0001174947-23-000270","cik":816956,"company_name":"CONMED Corp","ticker":"CNMD","form_type":"8-K","filed_at":"2023-02-27T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"CONMED declares $0.20 quarterly dividend, payable April 5, 2023","summary_kind":"llm","event_type":"dividend","confidence":"high","bullets":["Quarterly cash dividend of $0.20 per share declared.","Record date: March 15, 2023; payment date: April 5, 2023.","Dividend is consistent with prior quarterly rate (no change announced)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":1068274236.9273432,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":327419,"accession_number":"0001174947-23-000151","cik":816956,"company_name":"CONMED Corp","ticker":"CNMD","form_type":"8-K","filed_at":"2023-02-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CONMED reports Q4 sales down 8.4%, adj. EPS down 60.7% on warehouse software disruption","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 sales $250.9M (-8.4% YoY); GAAP EPS $0.86 vs $0.75 YoY; adjusted EPS $0.42 vs $1.07.","Full-year sales $1,045.5M (+3.4%); GAAP net loss per share $2.68; adjusted EPS $2.65 (-17.4%).","Q4 disruptions from new warehouse management system; management cites daily shipping now at or above historical rates.","2023 guidance: revenue $1.17B-$1.22B, adjusted EPS $3.20-$3.45, with FX headwind of $0.20-$0.25 per share.","Completed acquisitions of In2Bones (June 2022) and Biorez (Aug 2022), contributing ~240bps to full-year growth."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.68,"consensus_revenue_estimate":null,"consensus_revenue_actual":1045472000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1068274236.9273432,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":345140,"accession_number":"0001193125-22-312677","cik":816956,"company_name":"CONMED Corp","ticker":"CNMD","form_type":"8-K","filed_at":"2022-12-27T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"CONMED amends credit agreement to replace LIBOR with Term SOFR benchmark","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Third Amendment to Seventh Amended and Restated Credit Agreement, dated Dec. 20, 2022.","Replaces LIBOR with Term SOFR for calculating interest; includes related technical changes.","Effectiveness subject to no objection from requisite lenders within five business days of notice.","No changes to borrowing capacity, financial covenants, or other debt terms beyond rate transition."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":1068274236.9273432,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":345139,"accession_number":"0001193125-22-299605","cik":816956,"company_name":"CONMED Corp","ticker":"CNMD","form_type":"8-K","filed_at":"2022-12-07T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"CONMED GC Daniel Jonas to retire by July 2026; Heather Cohen succeeds","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["General Counsel Jonas transitions to Special Counsel & Corporate Secretary; retirement set for July 1, 2026.","Heather Cohen named EVP and Chief Human Resources and Legal Officer, succeeding Jonas.","Jonas receives $400k base salary with 60% target bonus through 2022, then 40% target through 2024; $896,295 final cash from Jan 2025.","Existing equity awards continue vesting through retirement; severance of $600k if terminated before Jan 2025.","One-year non-compete and non-solicit; indefinite confidentiality and non-disparagement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1068274236.9273432,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":345138,"accession_number":"0001174947-22-001248","cik":816956,"company_name":"CONMED Corp","ticker":"CNMD","form_type":"8-K","filed_at":"2022-12-05T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"CONMED declares quarterly dividend of $0.20 per share payable Jan 5, 2023","summary_kind":"llm","event_type":"dividend","confidence":"high","bullets":["Dividend of $0.20 per common share declared.","Record date for dividend: December 16, 2022.","Payment date: January 5, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1068274236.9273432,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":345137,"accession_number":"0001193125-22-285239","cik":816956,"company_name":"CONMED Corp","ticker":"CNMD","form_type":"8-K","filed_at":"2022-11-15T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"CONMED withdraws FY2022 outlook due to warehouse software disruption; provides FY2023 guidance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Service level disruptions from new warehouse software impacted Q4 shipments; backlog peaked at $35M, now $28M.","Withdrawal of FY2022 outlook attributed solely to temporary software implementation issues.","FY2023 revenue guidance: $1.170B-$1.230B; adjusted EPS guidance: $3.20-$3.50.","Daily shipment volumes have returned to normal; backlog expected to be shipped in coming weeks.","CEO and CFO to discuss at Stifel 2022 Healthcare Conference on Nov 15, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1068274236.9273432,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":345136,"accession_number":"0001174947-22-001093","cik":816956,"company_name":"CONMED Corp","ticker":"CNMD","form_type":"8-K","filed_at":"2022-10-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CONMED Q3 sales $275.1M (+10.6% YoY); adjusted EPS $0.77 misses prior year; narrows 2022 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Sales $275.1M +10.6% as reported, +12.1% constant currency; domestic +14.2%, international +6.2% as reported.","GAAP diluted EPS $1.48 (vs $0.47 Q3 2021); adjusted diluted EPS $0.77 (vs $0.80) down 3.8%.","Full-year 2022 revenue guidance narrowed to $1.1B-$1.115B; adjusted EPS guidance lowered to $3.21-$3.28 from $3.25-$3.45.","Closed Biorez acquisition on Aug 9, 2022; integrates with recent In2Bones acquisition.","Orthopedic Surgery sales $118.6M +12.2% as reported; General Surgery $156.5M +9.4%. Single-use +15.1%, capital -8.5%."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.59,"consensus_revenue_estimate":null,"consensus_revenue_actual":794605000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1068274236.9273432,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":361603,"accession_number":"0001174947-22-000946","cik":816956,"company_name":"CONMED Corp","ticker":"CNMD","form_type":"8-K","filed_at":"2022-08-11T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"CONMED declares $0.20 quarterly dividend, payable Oct 5 to holders of record Sep 15","summary_kind":"llm","event_type":"dividend","confidence":"high","bullets":["Quarterly cash dividend of $0.20 per share declared.","Payable on October 5, 2022 to shareholders of record as of September 15, 2022.","This represents a regular quarterly dividend; no change in rate indicated."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1068274236.9273432,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-08-11T23:59:59+00:00|361603"}